# Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer

> **NCT00052728** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** tamoxifen citrate
- **DRUG:** tipifarnib

## Key facts

- **NCT ID:** NCT00052728
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052728, "Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00052728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*